InsiderTrades.com logo
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
From Traders Agency   |   Ad
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Click here now for the full details of this stock that’s set to rocket in the AI revolution…

EFTR Insider Trading

Insider Ownership Percentage: 8.40%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $371,581.50

eFFECTOR Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at eFFECTOR Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

eFFECTOR Therapeutics Share Price & Price History

Current Price: $1.94
Price Change: ▲ Price Increase of +0.16 (8.99%)
As of 04/23/2024 01:00 AM ET

This chart shows the closing price history over time for EFTR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Exposed: 10 CENT Crypto to Explode April 20th?
From True Market Insiders   |   Ad
Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin
Click For My #1 FREE Crypto for 2024

eFFECTOR Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/27/2023Sr One Capital Management, LlcMajor ShareholderSell24,366$15.25$371,581.5072,856View SEC Filing Icon  
10/4/2022Christopher B. EhrlichDirectorBuy13$14.25$185.251,408View SEC Filing Icon  
9/26/2022Christopher B. EhrlichDirectorBuy754$13.75$10,367.501,394View SEC Filing Icon  
8/3/2022Presidio Management Group X LlMajor ShareholderSell2,375$20.00$47,500.005,102View SEC Filing Icon  
8/1/2022Presidio Management Group X LlMajor ShareholderSell1,068$19.75$21,093.005,208View SEC Filing Icon  
7/27/2022Presidio Management Group X LlMajor ShareholderSell1,746$22.25$38,848.505,280View SEC Filing Icon  
7/25/2022Presidio Management Group X LlMajor ShareholderSell91$23.25$2,115.755,336View SEC Filing Icon  
7/22/2022Presidio Management Group X LlMajor ShareholderSell304$22.75$6,916.005,339View SEC Filing Icon  
7/20/2022Presidio Management Group X LlMajor ShareholderSell401$25.00$10,025.005,351View SEC Filing Icon  
7/18/2022Presidio Management Group X LlMajor ShareholderSell839$27.00$22,653.005,367View SEC Filing Icon  
7/15/2022Presidio Management Group X LlMajor ShareholderSell1,836$27.75$50,949.005,392View SEC Filing Icon  
6/23/2022Brian M Jr. GallagherDirectorBuy1,200$39.75$47,700.001,200View SEC Filing Icon  
6/7/2022Michael ByrnesCFOBuy1,000$33.25$33,250.001,169View SEC Filing Icon  
6/7/2022Stephen T WorlandInsiderBuy800$34.25$27,400.008,599View SEC Filing Icon  
5/18/2022Presidio Management Group X LlMajor ShareholderSell563$43.25$24,349.755,460View SEC Filing Icon  
5/16/2022Presidio Management Group X LlMajor ShareholderSell510$43.75$22,312.505,492View SEC Filing Icon  
5/13/2022Presidio Management Group X LlMajor ShareholderSell904$46.00$41,584.005,508View SEC Filing Icon  
5/11/2022Presidio Management Group X LlMajor ShareholderSell200$58.75$11,750.005,549View SEC Filing Icon  
5/9/2022Presidio Management Group X LlMajor ShareholderSell160$63.50$10,160.005,605View SEC Filing Icon  
2/18/2022Christopher B. EhrlichDirectorBuy40$107.50$4,300.00View SEC Filing Icon  
2/14/2022Christopher B. EhrlichDirectorBuy80$111.25$8,900.00View SEC Filing Icon  
2/8/2022Christopher B. EhrlichDirectorBuy40$123.00$4,920.00View SEC Filing Icon  
2/3/2022Christopher B. EhrlichDirectorBuy200$128.75$25,750.00View SEC Filing Icon  
1/27/2022Christopher B. EhrlichDirectorBuy200$132.50$26,500.00View SEC Filing Icon  
12/2/2021Jonathan D. RootDirectorSell324$142.00$46,008.00View SEC Filing Icon  
12/1/2021Presidio Management Group X LlMajor ShareholderSell769$161.00$123,809.00View SEC Filing Icon  
11/30/2021Jonathan D. RootDirectorSell1,096$163.25$178,922.00View SEC Filing Icon  
11/29/2021Presidio Management Group X LlMajor ShareholderSell1,030$167.50$172,525.00View SEC Filing Icon  
11/26/2021Jonathan D. RootDirectorSell201$175.25$35,225.25View SEC Filing Icon  
11/24/2021Jonathan D. RootDirectorSell1,460$184.00$268,640.00View SEC Filing Icon  
11/23/2021Presidio Management Group X LlMajor ShareholderSell595$185.00$110,075.00View SEC Filing Icon  
11/22/2021Jonathan D. RootDirectorSell1,047$196.50$205,735.50View SEC Filing Icon  
11/19/2021Jonathan D. RootDirectorSell289$203.00$58,667.00View SEC Filing Icon  
11/18/2021Presidio Management Group X LlMajor ShareholderSell669$213.25$142,664.25View SEC Filing Icon  
11/17/2021Jonathan D. RootDirectorSell409$228.25$93,354.25View SEC Filing Icon  
11/16/2021Presidio Management Group X LlMajor ShareholderSell332$235.50$78,186.00View SEC Filing Icon  
11/15/2021Jonathan D. RootDirectorSell202$245.25$49,540.50View SEC Filing Icon  
11/12/2021Presidio Management Group X LlMajor ShareholderSell480$251.75$120,840.00View SEC Filing Icon  
11/11/2021Jonathan D. RootDirectorSell480$259.25$124,440.00View SEC Filing Icon  
11/10/2021Presidio Management Group X LlMajor ShareholderSell1,360$261.00$354,960.00View SEC Filing Icon  
11/9/2021Jonathan D. RootDirectorSell1,151$275.00$316,525.00View SEC Filing Icon  
See Full Table
Exposed: 10 CENT Crypto to Explode April 20th?
From True Market Insiders   |   Ad
Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin
Click For My #1 FREE Crypto for 2024

SEC Filings (Institutional Ownership Changes) for eFFECTOR Therapeutics (NASDAQ:EFTR)

57.67% of eFFECTOR Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at EFTR by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

eFFECTOR Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/13/2023Column Group LLC4,026,224$2.42M1.6%-6.6%9.496%Search for SEC Filing on Google Icon
11/2/2023Sonora Investment Management Group LLC125,000$75K0.0%N/A0.295%Search for SEC Filing on Google Icon
6/5/2023EP Wealth Advisors LLC17,607$1.65M0.0%N/A0.042%Search for SEC Filing on Google Icon
5/5/2023Carlyle Group Inc.4,822,114$1.69M0.1%N/A11.373%Search for SEC Filing on Google Icon
8/16/2022Callan Capital LLC20,000$28K0.0%N/A0.048%Search for SEC Filing on Google Icon
8/2/2022Resolute Financial LLC30,000$43K0.0%N/A0.072%Search for SEC Filing on Google Icon
8/1/2022Parallel Advisors LLC1,693,559$2.41M0.1%+150.0%4.092%Search for SEC Filing on Google Icon
4/28/2022Parallel Advisors LLC677,452$2.74M0.1%N/A1.637%Search for SEC Filing on Google Icon
2/15/2022SR One Capital Management LP6,822,114$56.49M31.9%N/A16.898%Search for SEC Filing on Google Icon
2/9/2022Alps Advisors Inc.51,942$0.43M0.0%N/A0.129%Search for SEC Filing on Google Icon
2/3/2022OUP Management Co. LLC1,025,697$8.49M3.8%N/A2.541%Search for SEC Filing on Google Icon
11/16/2021Verition Fund Management LLC24,667$0.35M0.0%N/A0.061%Search for SEC Filing on Google Icon
11/15/2021Abingworth LLP4,822,114$67.03M15.2%N/A11.964%Search for SEC Filing on Google Icon
11/15/2021Sectoral Asset Management Inc2,882,744$40.50M3.4%N/A7.153%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
eFFECTOR Therapeutics logo
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
Read More on eFFECTOR Therapeutics

Today's Range

Now: $1.94
Low: $1.78
High: $1.99

50 Day Range

MA: $10.18
Low: $1.70
High: $16.95

52 Week Range

Now: $1.94
Low: $1.60
High: $37.00

Volume

149,612 shs

Average Volume

331,532 shs

Market Capitalization

$7.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52

Who are the company insiders with the largest holdings of eFFECTOR Therapeutics?

eFFECTOR Therapeutics' top insider investors include:
  1. Sr One Capital Management, Llc (Major Shareholder)
  2. Stephen T Worland (Insider)
  3. Presidio Management Group X Ll (Major Shareholder)
  4. Christopher B Ehrlich (Director)
  5. Brian M Jr Gallagher (Director)
  6. Michael Byrnes (CFO)
Learn More about top insider investors at eFFECTOR Therapeutics.
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
From Traders Agency   |   Ad
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Click here now for the full details of this stock that’s set to rocket in the AI revolution…